title: [Pleiotropic effects of therapy in endothelial dysfunction syndrome].
abstract: Endothelial dysfunction syndrome initiates and usually accompanies the atherosclerotic process. Through their antioxidative, antiinflammatory, antiproliferative and antithrombotic role, the angiotensin-converting enzyme inhibitors, statins, the third generation of calcium antagonists, aspirin and salicylate derivates slow down, stop and improve the endothelial dysfunction, being a real therapy of atherosclerosis.
authors.affiliation: Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi, Facultatea de Medicină, Centrul de Cardiologie Iaşi.
authors.forename: L
authors.initials: L
authors.lastname: Macovei
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000503:physiopathology; D001241:Aspirin / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004095:Dihydropyridines / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin